Aim: We investigated uptake of short-course chemo-radiotherapy and compared outcomes with other treatment schedules in elderly patients with glioblastoma (GBM). Methods: Patients aged 65 or over with a diagnosis of GBM were identified from an 18-month period from three centers in the UK. The primary end point of this study was overall survival from the date of diagnosis. Results: The analysis included 210 patients. Overall median survival was 5.0 months. Approximately 31.9% of patients received combined chemoradiation; multivariate analysis showed that patients who received standard chemoradiation were at a reduced risk of death than those receiving hypofractionated chemoradiation. Discussion: In this retrospective study, patients treated w...
Objectives: The optimal treatment for elderly patients (age >70 years) with glioblastoma (GBM) re...
Many clinical trials have shown that the most important prognostic variable in patients with maligna...
Nils D Arvold,1 David A Reardon2 1Department of Radiation Oncology, Dana-Farber/Brigham and Women...
Aim: We investigated uptake of short-course chemo-radiotherapy and compared outcomes with other trea...
The appropriate treatment approach for elderly patients with glioblastoma multiforme (GBM) is unclea...
OBJECTIVES:: Age is an unfavorable prognostic factor in glioblastoma multiforme (GBM). To assess the...
Background: The optimal radiotherapy regimen in elderly patients with glioblastoma treated by chemor...
BACKGROUND: Glioblastoma is usually diagnosed around the age of 60-70 years. Patients older than 65&...
Objective: Glioblastoma (GBM) is the commonest primary malignant brain tumour amongst the adult ...
OBJECTIVES: Age is an unfavorable prognostic factor in glioblastoma multiforme (GBM). To assess the...
(1) Background: Studies in elderly patients over the age of 65 with glioblastoma have shown survival...
Aims: There is now evidence to support giving single-agent chemotherapy, radiotherapy or hypofrac...
Abstract Glioblastoma (GBM) is frequent in elderly patients, but their frailty provokes debate regar...
Median age at diagnosis in patients with glioblastoma (GB) is slowly increasing with an aging popula...
Objective: To evaluate the effects of combined treatments on the outcome and survival of elderly (≥ ...
Objectives: The optimal treatment for elderly patients (age >70 years) with glioblastoma (GBM) re...
Many clinical trials have shown that the most important prognostic variable in patients with maligna...
Nils D Arvold,1 David A Reardon2 1Department of Radiation Oncology, Dana-Farber/Brigham and Women...
Aim: We investigated uptake of short-course chemo-radiotherapy and compared outcomes with other trea...
The appropriate treatment approach for elderly patients with glioblastoma multiforme (GBM) is unclea...
OBJECTIVES:: Age is an unfavorable prognostic factor in glioblastoma multiforme (GBM). To assess the...
Background: The optimal radiotherapy regimen in elderly patients with glioblastoma treated by chemor...
BACKGROUND: Glioblastoma is usually diagnosed around the age of 60-70 years. Patients older than 65&...
Objective: Glioblastoma (GBM) is the commonest primary malignant brain tumour amongst the adult ...
OBJECTIVES: Age is an unfavorable prognostic factor in glioblastoma multiforme (GBM). To assess the...
(1) Background: Studies in elderly patients over the age of 65 with glioblastoma have shown survival...
Aims: There is now evidence to support giving single-agent chemotherapy, radiotherapy or hypofrac...
Abstract Glioblastoma (GBM) is frequent in elderly patients, but their frailty provokes debate regar...
Median age at diagnosis in patients with glioblastoma (GB) is slowly increasing with an aging popula...
Objective: To evaluate the effects of combined treatments on the outcome and survival of elderly (≥ ...
Objectives: The optimal treatment for elderly patients (age >70 years) with glioblastoma (GBM) re...
Many clinical trials have shown that the most important prognostic variable in patients with maligna...
Nils D Arvold,1 David A Reardon2 1Department of Radiation Oncology, Dana-Farber/Brigham and Women...